FDA OK's Novartis' Blood-Pressure Drug
Posted on: Tuesday, 6 March 2007, 12:00 CST
Novartis said Tuesday the U.S. Food and Drug Administration approved Tekturna, the first in a new class of high-blood-pressure medications.
Tekturna, a direct renin inhibitor, targets the enzyme renin, which plays a role in causing hypertension. Novartis said the drug will be available in March.
Many patients require two or more medicines to control their blood pressure, said James Shannon, Novartis' global head of development. As a new treatment approach, Tekturna has the potential to help these patients manage their disease.
The FDA approval is for monotherapy or in combination with other high-blood-pressure medications.
Novartis said it is committed to conducting a large outcome trial program to evaluate the long-term effects of Tekturna and direct renin inhibition.
Source: United Press International
Related Articles
- Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
- Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
- Novartis Gets OK for Blood Pressure Drug
- Novartis Blood Pressure Drug Approved in US
- Tekturna(R) - The First New Type of High Blood Pressure Medicine In More Than a Decade - Receives Its First Approval in the US
- New Drugs From Novartis and Daiichi Sankyo Will Achieve Blockbuster Status in the Hypertension Drug Market
- Novartis Blood Pressure Pill Cleared in EU
- Novartis blood pressure pill shows 1-year benefits
- Suddenly Sick: New Blood-Pressure Guidelines Pay Off -- for Drug Companies
 |
 |
User Comments (0)
RSS Feeds